Menu Search
Equities

Enzon Pharmaceuticals Inc

EZ1:DUS

Enzon Pharmaceuticals Inc

Actions
  • Price (EUR)0.101
  • Today's Change0.00 / 0.00%
  • Shares traded36.00
  • 1 Year change-33.55%
  • Beta--
Data delayed at least 15 minutes, as of Jul 08 2024 07:10 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Enzon Pharmaceuticals, Inc. (Enzon) is an acquisition vehicle company. The Company intends to become an acquisition platform. The Company utilizes its net operating loss carryforwards (NOLs) and improves stockholder value. It manages its source of royalty revenues from existing licensing arrangements with other companies.

  • Revenue in USD (TTM)0.00
  • Net income in USD221.00k
  • Incorporated1983
  • Employees0.00
  • Location
    Enzon Pharmaceuticals Inc20 Commerce Drive, Suite 135CRANFORD 07016United StatesUSA
  • Phone+1 (732) 980-4500
  • Fax+1 (302) 655-5049
  • Websitehttp://enzon.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.